BioLineRx Ltd. American Depositary Shares (BLRX)

About BLRX

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

20

Website

www.biolinerx.com/

Fundamentals

1-day range

$2.76$2.85

Market cap

$11.56M

P/E (trailing)

Infinity

P/E (forward)

-4.31

EPS (trailing)

$-0.00

Dividend yield

—

Beta

0.64

Avg. volume

17.5K

Dividend pay date

July 15, 2019

BioLineRx Ltd. American Depositary Shares Competitors

Chosen by industry and closest market cap.

• BLRX

  BioLineRx Ltd. American Depositary Shares

  $2.61

  ▼ 5.43%
  Market cap $11.56MP/E Infinity
  $1.1$2.4
• PHIO

  Phio Pharmaceuticals Corp. Common Stock

  $1.13

  ▲ 0.45%
  Market cap $11.97MP/E —
  $0.8127$4.19
• AKTX

  Akari Therapeutics plc ADS

  $11.03

  ▲ 22.42%
  Market cap $12.88MP/E Infinity
  $3.02$49.6
• COCP

  Cocrystal Pharma Inc. Common Stock

  $1.11

  ▼ 2.63%
  Market cap $12.96MP/E —
  $0.76$2.67
• GDTC

  CytoMed Therapeutics Limited Ordinary Shares

  $0.92

  ▼ 4.17%
  Market cap $9.50MP/E —
  $0.6801$3.68
• AEON

  AEON Biopharma Inc. Class A Common Stock

  $0.3095

  ▲ 5.27%
  Market cap $14.41MP/E —
  $0.1772$1.45
• PTN

  Palatin Technologies Inc. Common Stock

  $10.48

  ▼ 0.10%
  Market cap $14.64MP/E 85.09
  $5.61$31

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

29.7K

Total value held

$68.5K

Institutional holders

13